Search
Now showing items 1-3 of 3
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
(2015-12)
OBJECTIVE: To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS). METHODS: Meta-analysis of phase III trials of licensed DMDs for ...
The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?
(2015-01-01)
©2014 Elsevier B.V. All rights reserved. If it is not feasible to develop licensed drugs to the stage that they can actually be prescribed for a new indication, can we justify, either ethically or economically, the undertaking ...